We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MDxHealth, Cerba HealthCare Announce Collaboration
News

MDxHealth, Cerba HealthCare Announce Collaboration

MDxHealth, Cerba HealthCare Announce Collaboration
News

MDxHealth, Cerba HealthCare Announce Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MDxHealth, Cerba HealthCare Announce Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MDxHealth SA and Cerba HealthCare Belgium have announced that they have signed a Collaboration Agreement to bring MDxHealth's SelectMDx(TM) for Prostate Cancer test to urology practitioners in France, Belgium and Luxembourg. Under the terms of this two-year agreement, Cerba HealthCare Belgium will offer the SelectMDx test through its laboratory network in France, Belgium and Luxembourg.

During the initial phase of the agreement, samples will be analyzed at MDxHealth's service-testing laboratory in Nijmegen, The Netherlands. The agreement will then move into a second phase, whereby the SelectMDx test will be transferred to the Molecular Biology Department of Cerba HealthCare's laboratory CRI in Zwijnaarde, Belgium.

"This exciting partnership with Cerba dramatically increases access to SelectMDx in Europe," stated Dr. Jan Groen, Chief Executive Officer, MDxHealth, "Cerba is a leading healthcare provider specializing in the delivery of advanced diagnostic assays and serving 15,000 patients per day through its 5,000 customers worldwide, who will now have access to SelectMDx."

"Compared to our current PCA3 marker, SelectMDx supports a broader segment of patients at risk of prostate cancer," added Dr. Els Decoster, Head of Molecular Biology and R&D at CRI. "We will therefore replace PCA3 with SelectMDx in our molecular test portfolio."

Advertisement